Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Chief Financial Officer | March 03, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viridian Therapeutics, Inc.\DE
Report date March 03, 2026 · Filed March 09, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,850 |
Reported balance
After 2026-03-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-03 · Tax withholding · Disposed 2,031 · Balance 7,850 F1: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 4, 2026 19:15 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionRestricted Stock Units · Derivative | 6,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092071 · ownership.xml · derivative · entry 5 Harmon Seth · CIK 0001993300 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,801 Underlying: Common Stock · 6,267 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 19:15 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Tax withholdingCommon Stock | 2,091 | $29.32 | $61,308.12 |
DisclosureSEC source: 0001193125-26-092071 · ownership.xml · nonDerivative · entry 2 Harmon Seth · CIK 0001993300 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,790 F5 · balance_after: Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 19:15 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 6,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-092071 · ownership.xml · nonDerivative · entry 1 Harmon Seth · CIK 0001993300 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. F5 · balance_after: Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). Read SEC document |
| March 03, 2026 Filed Mar 9, 2026 19:49 UTC Amendment | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Tax withholdingCommon Stock | 2,031 | $30.19 | $61,315.89 |
DisclosureSEC source: 0001193125-26-099023 · ownership.xml · nonDerivative · entry 1 Harmon Seth · CIK 0001993300 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,850 F1 · shares: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4. F1 · balance_after: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 19:15 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantRestricted Stock Units · Derivative | 20,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-092071 · ownership.xml · derivative · entry 4 Harmon Seth · CIK 0001993300 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,550 Underlying: Common Stock · 20,550 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 19:15 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 102,850 | $0.00 Strike: $30.25 | $0.00 |
DisclosureSEC source: 0001193125-26-092071 · ownership.xml · derivative · entry 3 Harmon Seth · CIK 0001993300 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,850 Underlying: Common Stock · 102,850 shares Expires 2036-03-02 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:12 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantRestricted Stock Units · Derivative | 25,068 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032884 · ownership.xml · derivative · entry 2 Harmon Seth · CIK 0001993300 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,068 Underlying: Common Stock · 25,068 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:12 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 150,407 | $0.00 Strike: $14.41 | $0.00 |
DisclosureSEC source: 0000950170-25-032884 · ownership.xml · derivative · entry 1 Harmon Seth · CIK 0001993300 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,407 Underlying: Common Stock · 150,407 shares Expires 2035-03-03 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 3, 2025. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 17:17 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 270,000 | $0.00 Strike: $13.76 | $0.00 |
DisclosureSEC source: 0000950170-23-063124 · ownership.xml · derivative · entry 1 Harmon Seth · CIK 0001993300 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2033-11-10 F1 · derivative.exercise_date: The option vests in equal monthly installments through November 10, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.